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ABSTRACT 
 
Serum regulation of Inhibitor of DNA Binding/Differentiation 1 expression by a 




Immediate Early Genes (IEGs) are expressed upon re-entry of quiescent cells into 
the cell cycle following serum stimulation.  These genes are involved in growth control 
and differentiation and hence their expression is tightly controlled.  Many IEGs are 
regulated through Serum Response Elements (SREs) in their promoters, which bind 
Serum Response Factor (SRF).   However, many other IEGs do not have SREs in their 
promoters and their serum regulation is poorly understood.  We have identified SRF-
independent IEGs in SRF-depleted fibroblasts. One of these, Id1, was examined more 
closely. We mapped a serum responsive element in the Id1 promoter and find that it is 
identical to a BMP Responsive Element (BRE).  The Id1 BRE is necessary and sufficient 
for the serum regulation of Id1.  Inhibition of the BMP pathway by siRNA depletion of 
Smad4, treatment with the BMP antagonist noggin, or the BMP receptor inhibitor 
dorsomorphin blocked serum induction of Id1. Further, BMP2 is sufficient to induce Id1 
expression.  
Given reports that SRC inhibitors can block Id1 expression, we tested the SRC 
inhibitor, AZD0530, and found that it inhibits the serum activation of Id1.  Surprisingly, 
this inhibition is independent of SRC or its family members.  Rather, we show that 
AZD0530 directly inhibits the BMP type I receptors.  Serum induction of the Id1 related 
gene Id3 also required the BMP pathway.  Given these and other findings we conclude 
that the Id family of IEGs is regulated by BMPs in serum through similar BREs.   This 
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Immediate	  Early	  Genes	  	  
In the late 1970’s, researchers realized that in response to the insect steroid 
hormone ecdysone, a group of genes were induced within 5-10 minutes of stimulation [1].    
These genes were transiently expressed and their expression led to the expression of a set 
of secondary response genes that are functionally distinct from the rapidly expressed 
genes [2].    These findings lead to the study of Immediate Early Genes (IEGs) in 
fibroblasts [3].    
When growth factors are removed from NIH3T3 mouse fibroblasts they become 
quiescent.    These cells enter a reversible, non-growing state; they stop dividing and do 
not replicate DNA.    These cells show no net change in cell number, however, a very 
small percentage of the quiescent cells transverse the cell cycle [4].  This implies that 
some cell death may occur.  A difference in the genes expressed in growing cells and 
quiescent cells was observed [5, 6].  Expression of c-fos, one of the earliest known IEGs 
is very low during the cell cycle but is highly and rapidly expressed upon growth factor 
stimulation of quiescent cells [7, 8].   
Upon re-stimulation with serum or specific growth factors, quiescent cells re-
enter the cell cycle [9].  Immediate Early Genes are expressed rapidly-within minutes, 
and transiently upon treatment with serum or growth factors [10-15].  The expression of 
these genes is independent of new protein synthesis [16] suggesting that is it is a 
relatively direct response to serum induction.    




IEGs are involved in a plethora of processes including growth [17], differentiation 
[18, 19], lineage determination [20], learning and memory [21].    Many of these genes 
are potent transcription factors responsible for the regulation of networks of other genes 
[22].  Others are DNA binding proteins, cytoskeletal protein, receptor subunits or 
secreted proteins.   These genes usually have high affinity TATA boxes in their core 
promoter, and short primary transcripts with few exons, and over representation of shared 
transcription factor binding sites in upstream sequences [2].    
c-fos, c-jun and c-myc are among the earliest discovered and most well studied 
IEGs.   Some of earliest evidence of c-fos and c-myc being IEGs came in the 1980’s 
when it was observed that their expression can be induced quickly in fibroblast cells 
which have been stimulated with purified growth factors [8, 23].    c-fos reaches its 
maximal RNA levels as early as 30 minutes following stimulation, while c-myc reaches 
its maximal RNA levels 60 minutes following growth factor treatment. 
The regulation of these IEGs is tightly controlled and misregulation can lead to 
many diseases including cancer, neurological disorders [24], bone remodeling disorders 
[25]  and other chronic diseases.   As reviewed in [26], IEG expression in many cancers 
is found to be sustained and abnormally high.   Understanding the transcriptional 
regulation of IEGs is an important step in understanding how their deregulation results in 
disease and finding better therapies for these diseases.   	  	  
Serum	  Response	  Elements	  	  
Hundreds of experimentally validated or hypothesized genes have a Serum 
Response Element (SRE) or CArG box in their promoter[27-30].  The consensus 




sequence of the SRE is a 10-bp cis-element, CC(AT)6GG.    DNA binding assays 
identified the critical need for an element in the c-fos promoter for binding to a factor 
[31].   Originally the CArG box was identified as a 23 bp element which showed dyad 
symmetry within the 5’ activating element of the c-fos promoter [31].    Around the same 
time another group [32] identified a common element in the promoter of  chicken, mouse, 
and human cardiac α-actin genes.  They called it the CArG box.  This muscle gene 
element lacked the dyad symmetry of the SRE [33].   Mutagenesis studies established the 
necessity of the CArG box in the regulation of the promoter activity of IEGs [32, 34].    
The CArG box is the core sequence of the SRE, although the two terms are used 
interchangeably.    Over the last couple decades CArG boxes in many IEGs, e.g. c-fos 
[31], Vinculin (vcl) [35], Cysteine rich protein 61 (cyr61) [36], Connective tissue growth 
factor (CTGF) [37], Early growth response 2 (egr2) [38] and α-actin [39] have been 
identified. 
 
Serum	  Response	  Factor	  	  
The MADs box family member [40], Serum Response Factor (SRF),  binds to the 
SREs of IEGs [24, 41-43].    The MADS box transcription factors were identified based 
on primary sequence similarity of the founding members MCM1(yeast), Agamous 
(plants), Deficiens (plants)  and SRF (animals) [44].  SRF has a MADS box, a conserved 
56 amino acid region that is made up of a basic DNA-binding domain, a dimerization 
domain, and an interface for protein-protein interactions [40].   
SRF is a 62-67 kDa, evolutionarily conserved [45] protein originally purified 
from HeLa extracts in complex with the CArG box of the SRE [42, 46]. It is ubiquitously 




expressed and binds SRE as a homodimer [45, 47].   The CArG box is important  for 
facilitation of SRF interaction with the SRE [31, 48-50].  SRF is activated by serum and 
like other IEGs, its induction is not dependent on de novo protein synthesis [45].    
The use of neutralizing sera showed that SRF is critical in skeletal muscle 
differentiation in vivo [51, 52].   SRF is critical for mesoderm formation during mouse 
embryogenesis [53].   However, SRF-/- embryonic stem (ES) cells can differentiate into 
mesoderm marker expressing cells in vitro and when introduced into nude mice they can 
form various cells types [54].    SRF also plays a key role in the differentiation of pro 
epicardial cells to coronary smooth muscle cells [55].   Although SRF-/- ES cells grow, 
they are deficient for IEG activation.   On the other hand, SRF-/- ES cells display altered 
cellular morphology, reduced cortical actin expression, and an impaired plating efficiency 
on gelatin.  In spite of these defects, the proliferation rates of SRF-/- ES cells are not 
substantially altered, signifying that SRF function is not required for ES cell cycle 
progression [47, 56]. 
SRF is constitutively present at the promoters of the genes it regulates and its 
binding does not change upon activation with growth factors [57].   Stimulation of 
quiescent cells with the growth factors in serum results in the activation of two pathways 
sufficient for SRE activation, the mitogen activated kinase (MAPK) and the RhoA 
GTPase pathways.  The MAPK pathway, through a cascade of factors, leads to the 
phosphorylation and activation of SRF co-factors, the ternary complex factors (TCFs). 
The TCF factors are ETS-like gene 1 (ELK1), Serum response factor accessory protein 1 
(SAP1) and ETS related protein NET (NET) [22, 58].   The small GTPase, RhoA, via 
another group of SRF co-transcriptional activators, also activates SRF. The coactivators   




are the myocardin related factors, Megakaryoblastic Leukemia1/2(MKL1/2), also known 
as MRTF-A, MRTF-B, Mal and BSAC [59-62].    
 
Ternary	  Complex	  	  	  
TCFs bind an E-twenty six (Ets) motif; CAGGAT, adjacent to the CArG box.  
TCF binding to the promoter is dependent on SRF [63].  Genetic foot printing studies 
showed that TCFs are present at the promoter even in unstimulated cells.   This indicated 
that the induction of these factors involved changes in transcriptional activation rather 
than DNA binding [57].    TCF binding is required for c-fos response to MAP kinase 
signaling.  When the TCF site in its promoter is mutated it is still able to be induced by 
whole serum but cannot be induced by stimuli such as phorbol myristate acetate (PMA) 
[64-66].   
The three Ets domain proteins which have been identified all have DNA binding 
properties and contain four regions of sequence homology called domains A, B and C 
and D [67-69].   DNA binding and cooperative interaction with SRF at the SRE is 
mediated by domains A and B [70, 71].  The B domain is necessary for the formation of 
the ternary complex [72] and interaction with SRF [73].  The C domain contains many 
(S/T) P MAP kinase phosphorylation sites [58, 74].   The D domain serves as the MAP 
kinase-docking site [75].     Once the kinases have docked they can then phosphorylate 
residues in the C domain, the transcriptional activation domain [75]. TCFs can be 
phosphorylated by the three major MAP kinase pathways in mammals, namely: ERK1/2; 
extracellular signal regulated kinase 1 and 2, JNK; c-Jun N terminal kinase and p38 [76, 
77].  Phosphorylation of the transcriptional activation domain of TCFs results in their 




increased transcriptional ability and formation of ternary complexes with SRF [74, 76, 
77].   SAP1 and Net also contain additional regions that confer the ability to repress 
transcription [78, 79].    
TCFs activate immediate early genes by formation of the ternary complex with 
SRF at the SREs [80].   Recruitment of TCFs to the promoter of IEGs requires both 
protein-protein and protein-DNA interactions [80].  In the presence of high affinity ets 
motifs some autonomous binding of TCF to SREs has been reported [72, 81, 82].   When 
TCFs are activated they bind to SRF. This interaction increases their affinity to the ets 
site of the c-fos SRE.   The SRF DNA binding domain and the B box are sufficient for 
this protein-protein interaction [70].   A quaternary complex has also been described on 
the c-fos promoter that contains an SRF duplex and two ELK1s [83, 84].    
Ternary complex formation and transcriptional activation is induced upon MAP 
kinase activation.  While the JNK and p38 cascades are activated by cytokines and stress, 
the ERK cascade responds to growth factors and mitogens.  The activation of TCFs 
results in the recruitment of activating co-factors such as CBP and p300.  Other activators 
and RNA polymerase ΙΙ are also recruited to the complex and transcription of the IEGs 
proceeds. In the absence of a signal the c-fos promoter is occupied by a multiprotein 
complex [57].  Phosphorylation of the TCF C-box results in the exchange of factors and 
the recruitment of p300 and a mediator complex that recruits RNA polymerase ΙΙ.  c-fos 
is activated through the histone acetyl transferase activity of the co-activators.  De-
phosphorylation of the TCF factors [85] or recruitment of co-repressors leads to the 
subsequent repression of c-fos promoter activity [86]. Phosphorylation may not always be 
necessary for recruitment of co-activators [87]. 





RhoA	  Pathway	  	  	  
The SRE can also be activated without TCF but the presence of SRF is required 
[64, 66].   Lysophosphatidic acid, a mitogen in serum and heteromeric G-proteins can 
activate a c-fos promoter, which is unable to bind TCF [88].   This response is mediated 
by RhoA, a member of the Ras super family of small GTPases [89].    The core SRE can 
be activated by activated forms of rhoA, rac and cdc42Hs, members of the Rho GTPase 
family,.  In addition, inhibition of RhoA blocks SRE activation in NIH3T3 cells [90].    
This pathway involves another group of co-factors, the myocardin related 
transcription factors (MRTFs) that comprise the cardiac and smooth muscle specific gene, 
myocardin and the ubiquitously expressed genes megakaryoblastic leukemia-1 (MKL1) 
and megakaryoblastic leukemia-2 (MKL2) [60].   MKL1/2 bind to the same region of 
SRF as TCF, therefore, the binding of MKL1/2 and TCF is mutually exclusive.  Since	  the	  TCF	  and	  RhoA	  pathways	  are	  complementary,	  the	  activation	  of	  the	  RhoA	  pathway	  of	  SRE	  induction	  is	  often	  apparent	  only	  after	  mutation	  of	  the	  TCF	  pathway	  [91]. 
RhoA activation leads to changes in the actin cytoskeleton. This results in changes in the 
nuclear localization and activation of MKL1/2 and consequently activation of SRF target 
gene expression [92-94].  
Myocardin is always nuclear and constitutively activates transcription [95].  
MKL1/2 have three RPEL domains in their N-terminal region that are required for actin 
binding [62, 94].	  	  The	  interaction	  between	  MKL1	  and	  SRF	  is	  facilitated	  by	  the	  glutamine-­‐rich	  region	  [96].	  	  	  Both	  the	  glutamine-­‐rich	  and	  basic	  regions	  have	  antagonistic	  effects	  on	  the	  nuclear	  import	  of	  MKL1.	  	  	  The	  leucine	  zipper	  (LZ)	  region	  




can	  mediate	  homo-­‐	  and	  hetero-­‐	  dimerization	  of	  the	  MKL1	  family	  members.	  	  	  The	  function	  of	  the	  SAP	  region	  is	  not	  well	  understood	  but	  has	  been	  involved	  in	  nuclear	  	  	   	   	  	  
 
Figure 1. 
Sequence similarity in MRTFs. Domain structures of the myocardin protein family. RPEL	  or	  actin	  binding	  domain,	  ++	  :	  Basic	  domain,	  B:	  B-­‐box,	  Q:	  glutamine	  rich	  domain,	  SAP	  domain,	  LZ:	  Leucine	  zipper	  and	  TAD:	  trans-­‐activation	  domain 	  matrix	  attachment	  in	  other	  proteins	  [97].	  	  The	  C-­‐terminal	  contains	  a	  transcriptional	  activation	  domain	  (TAD)	  (Figure	  1).	  	  Deletion	  of	  these	  TAD	  regions	  creates	  a	  dominant	  negative	  mutant	  [98].	  	  MKL1 phosphorylation upon serum activation results 
in its nuclear export and inactivation [99]. 
Activation of RhoA causes stress fiber formation and a reduction in available 
monomeric G-actin [100].   MKL1/2 is kept in the cytoplasm by being bound to G-actin. 
When cells are treated with mitogens, stress fibers form; this causes a reduction in the 
pool of G actin and MKL1/2 migrates to the nucleus.  When in the nucleus these co-
factors bind to SRF and activate IEG expression [94].   MKL1/2 is needed for the 
expression of many IEGs [30, 62].    Figure 2 summarizes the two SRF dependent 
pathways of IEG activation. 
Some IEGs do not have clear SREs in their promoters.  Their induction may be 
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IEGs do not require SRF for their serum induction.  It is important to discover whether 
there is another common sequence element or pathway through which these SRE-lacking, 















Model of serum induction. 
The MAPK and the RhoA pathways activate iEGs.   Both pathways require SRF. 
 
HLH	  proteins	  	  
An important class of gene regulatory proteins contains the basic-helix-loop-helix 
(bHLH) domain and is involved in proliferation and differentiation pathways [101, 102].   
The bHLH domain is a protein motif that is common to a group of transcriptional 
regulators [103, 104].  More than twenty-seven members of this family have been 
identified [105].   These DNA binding proteins serve as regulatory factors whose 





















tissue specific phenotypes.  These proteins are well conserved and are present in 
organisms ranging from yeast, nematodes, Drosophila melanogaster, and  Xenopus 
Laevis to chickens and mammals.   bHLH proteins are crucial for the regulation of many 
cellular processes including, cell growth, differentiation, regulation of lineage 
commitment,  cell fate decisions, and the timing of differentiation [103, 106, 107] .    
bHLH proteins are very similar in their structure [103].   These factors have a 
bHLH domain that is made up of a stretch of about 18 hydrophilic and basic amino acids 
at the N-terminal end of the domain, followed by two regions of hydrophobic residues 
which forms an amphipathic α-helix separated by an intervening loop [103].  They have a 
highly conserved basic region which allow them to bind the major groove of DNA.   
These proteins are all capable of homodimerization and heterodimerization [101, 108, 
109].   The family member bound by a bHLH is crucial in the determination of its role in 
different cellular processes.   
The bHLH proteins bind to a consensus sequence called an E box, CANNTG 
[110].    bHLH factors are often regulated through protein-protein interactions.  Some 
members of this family lack the basic domain and therefore inhibit DNA binding by the 
factor with which they heterodimerize.  Members of this group include the Inhibitor of 
DNA binding (Id) family and Drosophila extramacrochaetae protein [108, 111].  bHLH 
genes are also  regulated by the availability of binding partners. Some members are 
repressed in a tissue specific manner, one example is MyoD [112].   myc on the other 
hand is more broadly expressed [113].   
There are seven known classes of bHLH families [114, 115].  These classes 
comprise more than 240 members.  Class I proteins, also known as the E proteins, include 




E12, E47, HEB, E2-2, and Daughterless.  These proteins are expressed in many tissues 
and capable of forming either homo or heterodimers [108].  Class II  includes members 
such as MyoD, myogenin, Atonal, NeuroD/BETA2, and the achaete-scute complex. 
These proteins show a tissue-restricted pattern of expression [108].  Class III includes the 
Myc family of transcription factors, TFE3, SREBP-1, and the microphthalmia- associated 
transcription factor, Mi.  Proteins of this class contain a Leucine Zipper domain adjacent 
to the HLH motif [116, 117].  Class IV includes Mad, Max, and Mxi; these molecules are 
capable of dimerizing with the Myc proteins or with one another [118-120].  Class V	  members are negative regulators of class I and class II HLH proteins. This group 
includes the Ids and Emc [121-123].   Class VI HLH proteins have as their defining 
feature a proline in their basic region.  This group includes the Drosophila proteins Hairy 
and Enhancer of split [124, 125].  Class VII HLH proteins are categorized by the 
presence of the bHLH-PAS domain and include members such as the aromatic 
hydrocarbon receptor (AHR), the AHR nuclear-translocator (Arnt), hypoxia-inducible 
factor 1a, and the Drosophila Single-minded and Period proteins [126].  Evolutionary 
classification of HLH factors has been proposed by Atchley et al [105]  based on 
phylogenetic analyses of amino acid sequences.  This classification is newer and used 
less often. 
 
Inhibitor	  of	  DNA	  Binding/	  Differentiation	  1	  	  
Inhibitor of DNA binding/differentiation 1 (Id1) is an IEG [127].  Inhibitor of 
DNA binding/ differentiation proteins were isolated as binding partners of the HLH 
family of transcription factors, namely E12, E47 and MyoD [121].  Id1 is expressed soon 




after treatment of quiescent cells with serum and this increased expression does not 
require de novo protein synthesis.  Id1 is a member of the HLH family of transcription 
factors that form heterodimers with other members of the HLH family [121, 128].   To 
date four members of this family, Id1-4 have been isolated [129-131].    
All the Id family members are capable of inhibiting the activity of other members 
of the HLH family of transcription factors.  The Id1 protein lacks a basic DNA-binding 
domain but it is capable of forming heterodimers with other HLH proteins [132].  These 
heterodimers are non functional; unable to bind DNA, thereby inhibiting the 
transcriptional activity of the bHLH proteins (Figure 3).  This is an important method of 
regulation of other HLH factors [133].    
Id1 is ubiquitously expressed [134].  Id1 expression appears in many tissues and 
its expression roughly correlates with the less differentiated phenotype [135-137].   The 
expression of Id1 is low in differentiation medium and this expression increases when 
cells are treated with mitogens in serum [127, 138]. The Id1 gene is highly expressed in 
undifferentiated, cycling cells and tumor cell lines. Id1 expression level decreases 
dramatically when cells undergo terminal differentiation [121, 139].	  	  Id1 functions as a 
regulator of cellular differentiation of muscle cells [121]. Id1 binds to muscle 
differentiation factors such as MyoD and inhibit its activity. This interaction prevents the 
binging of MyoD to DNA and therefore activation of muscle specific genes regulated 
MyoD.  When Id1 is over expressed, cellular differentiation in many cell culture systems 
and in transgenic mice is blocked [121, 140-142].   Inhibiting Id protein synthesis by 
antisense oligonucleotides and microinjection of anti-Id1 antibodies prevents the reentry 
of arrested cells into the cell cycle [138, 139, 143].  This implies that Id1 is required for 




this process. Id1 over expression overcomes the growth inhibitory effect of E2A, 
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Figure 3.  Inhibition of transcription by Id1. 	  
Id1	  promoter	  regulation	  	  
The TGF-β family of growth factors regulates Id1.   Id1 is upregulated by 
prolonged exposure to Transforming Growth Factor-β1 (TGF-β1) in epithelial cells [146].   
Smad3 and ATF binding elements in the Id1 promoter mediate this upregulation.    Id1 is 
also upregulated by TGF-β1 in the human mammary gland cell line, MCF10A [147] and 
this regulation is also mediated by Smad3. Upon TGF-β stimulation, activated Smad3 can 
recruit transcriptional activators such as p300/CBP [148]. Liang et al. [147] showed that 




TGF-β1 induces H3 and H4 histone acetylation of the mId1 promoter in MCF10A cells. 
This is likely because of acetylation activity of p300/CBP [149].  Id1 is also suppressed 
by TGF-β1 in some cell lines [146]. For example utilizing RNAi technology, Id1 
expression was suppressed in a Smad3-dependant manner in LoVo cells when treated 
long with TGF-β1 long-term [150].  Kang et al. [146] showed that repression of Id1 is a 
general feature of the TGFβ cytostatic program. Treatment of Mouse Embryonic 
Fibroblasts (MEFs) with TGFβ long-term results in the activation of the TGFβ mediator, 
Smad3.  Smad3 activates the expression of ATF3 and recruits it to the Id1 promoter.  
This is facilitated by Smad Binding Elements (SBEs) located between  -1850 to -1467, -
1265 to -926 and -255 to +47 of the mId1 promoter [147].  Smad3 interacts with HDAC4 
and HDAC5 to repress the Runx2 gene [151]. When this happens Smad3 acts as a 
transcriptional repressor.  Upon TGF-β activation of ATF3, Smad3 may act as a repressor 
of the Id1 promoter in a similar manner.  This repression correlates with decreased levels 
of acetylated H3. Therefore, Id1 regulation by TGF-β1 is a complicated event, shifting 
from early induction to late repression [147].  The early induction of Id1 may be 
necessary for its inhibition of differentiation while its late repression may allow the right 
balance to promote cell cycle progression.  
 
Several groups have shown that Id1 is upregulated in response to Bone 
Morphogenetic Protein (BMP) signaling [152-155].   I will introduce Smads and the 
BMP pathway before I discuss this regulation. 
 





Smads are intracellular proteins that transduce extracellular signals from transforming 
growth factor beta ligands to the nucleus. In the nucleus they activate downstream gene 
transcription [156]. These genes are homologous to the Drosophila protein, mothers 
against daughters (MAD) and the Caenorhabditis elegans protein, small body size 
(SMA). Eight Smad proteins are encoded in the human and mouse genomes, four in 
Drosophila, and three in C. elegans [157].  There are three classes of Smads. The receptor 
regulated Smads (R-Smads) includes Smad1, Smad2, Smad3, Smad5, and Smad8/9.  The 
common mediator Smad (co-Smad), Smad4 is the only member of the second group.  
Smad4 interacts with the R-Smads to transduce signals to the nucleus. The inhibitory or 
antagonistic Smads (I-Smad) make up the final group.   This group includes Smad6 and 
Smad7. These Smads interfere with Smad-Smad or Smad-receptor interactions. Smad2 
and Smad3 are the main activators for TGF-β, Nodal and activin signaling.  Smad1, 
Smad5 and Smad8 are the principal factors for BMP and anti-Mullerian receptors [158].  
Smad proteins consist of about 500 amino acids which comprise two key domains 
separated by a globular domain [159].  They have an N-terminal Mad Homology 1 
(MH1) and a C-terminal MH2 domain.  The MH1 domain is important for DNA binding 
and is well conserved among the Smads except Smad6 and Smad7.   This domain is 
followed by a linker domain, which contains binding sites for Smad ubiquitination-
related factor (Smurf) ubiquitin ligases, phosphorylation sites for several classes of 
kinases, and in Smad4 a nuclear export signal (NES). The Smad MH2 domain is highly 
conserved, is one of the most versatile protein-interacting modules in signal transduction 
and is responsible for Smad interaction with receptors of the TGF-β family [160]. Its 




structure contains several α-helices and loops which surround a β-sandwich [161].  It 
resembles the forkhead-associated domain (FHA), a phosphopeptide-binding domain 
common in transcription and signaling factors [162]. R Smads have a conserved C-
terminal motif, Ser–X–Ser, that is phosphorylated by the activated receptor [158].  
Smad4 does not have this motif [158]. 
 Smads are activated when they are phosphorylated in their MH2 domain by activated 
TGF-β family receptors.  This decreases their affinity for their cytoplasmic anchors and 
increases affinity for their nuclear partners [159, 163].  Smads migrate to the nucleus as a 
trimer (two R-Smads and one Smad4).  In the nucleus the Smad complex directly binds 
DNA and affect gene transcription. Once in the nucleus the Smad4/R-Smad complex 
binds to the promoter of target genes and recruits co-activators or repressors.  The co-
Smad, Smad4 binds to a SBE; GTCT/AGAC of target genes [158].  BMP specific Smads 
bind a BMP Response Element (BRE).  A BRE is a GC rich sequence, i.e. GCCGNC or 
GRCGNC [164, 165]. 
 R-Smads interact with coactivators such as p300 and CBP. CBP and p300 have histone 
acetyl transferase (HAT) domains. HATs increase gene transcription by changing the 
nucleosome and increasing the accessibility to the general transcription machinery [166]. 
Nuclear R-Smads are later dephosphorylated and returned to the cytoplasm where 
they can undergo future rounds of activation by phosphorylation. Smad4 constantly 
shuttles between the nucleus and the cytoplasm [167]. When the R-Smads are 
phosphorylated they bind Smad4. This masks the NES signal of Smad4 and the pair 
translocates to the nucleus. This decreases the nuclear export of Smad4.  When R-Smads 
are dyphosphorylated, the NES of Smad4 is exposed and Smad4 is exported from the 




nucleus [158].  
	  
Bone	  Morphogenetic	  Proteins	  	  
Bone Morphogenetic Proteins (BMPs) are growth factors which belong to the 
TGFβ super family of receptors [168].   BMPs were discovered in the 1970’s as factors 
necessary for bone formation [169]. It was later understood that a group of proteins, 
BMPs, were responsible for the formation of bone [170, 171]. BMPs are able to generate 
bones in extra-skeletal ectopic sites [172]. BMPs are the largest subgroup of the TGF-β 
super family of growth factors [170, 173].   Over twenty members of the BMP family 
have been identified [174, 175]. 
BMPs are critical in many processes including growth, differentiation, apoptosis, 
embryonic development, mesoderm patterning, bone formation, craniofacial and limb 
development [176-178].  They are generally made by cells in the region of their 
physiological requirement and therefore act in an autocrine or paracrine manner [179].  
BMPs are divided into four sub-groups BMP2/4, BMP5/6/7/8a/8b, BMP9/ 10, and 
BMP12/13/14 [180, 181].  This classification was made based on the function of BMPs 
determined by genetic mutations (see [182] for a detailed review). 
BMPs are synthesized as large precursors of about 400-500 amino acids. They 
consist of an N-terminal signal peptide that directs secretion, a prodomain for proper 
folding and a C-terminal mature peptide [183, 184].  Carboxy terminal mature proteins 
are proteolytically cleaved after dimerization of the precursor.  They are cleaved in the 
prodomain at an Arg-X-X-Arg sequence by serine endoproteases, except for BMP4, 
which is cleaved by Furin, PC6 and PC7 [185]. Active BMPs contain 50-100 amino acids 




with seven cysteines. Six of these cysteines form three intramolecular disulphide bonds 
known as cysteine knots.  The seventh cysteine is necessary for dimerization with another 
BMP monomer by forming a covalent disulphide bond, thus forming a biologically active 
signaling molecule [186].  With a few exceptions, most BMPs function as homodimers or 
heterodimers. BMP2 and BMP4 are constituents of serum [187-189]. 
As BMPs are so potent, there are several ways to modulate their activity.   
Extracellular antagonists such as noggin, chordin and follistatin regulate the BMP 
pathway.  Noggin limits the activity of BMP4 by binding to BMP4.  This interaction 
prevents BMP4 from binding to the cognate receptor [190, 191].  The BMP pathway is 
also inhibited by I-Smads. These Smads bind to the type 1 receptors, thus preventing the 
phosphorylation of R- Smads by the receptors and preventing the Smad-Smad or Smad-
receptor complex formation. Smads are also be regulated by protein degradation via the 
ubiquitin proteasome. Smurf1 and Smurf2 are Smad-specific E3 ubiquitin ligases that 
selectively interact with BMP R-Smads and mediate their ubiquitination and proteasomal 
degradation [192, 193]. There are also co-transcriptional repressors which suppress BMP 
signaling [193]. One repressor, ski can bind to the Smad protein complexes that form in 
response to BMP.  ski represses the ability of BMPs to activate BMP target genes through 
disruption of a functional Smad complex and through recruitment of transcriptional co-
repressors [194] . 
BMPs bind transmembrane type 1 and type 11 receptors [195, 196].    These 
receptors encode serine/threonine kinases made up of a short extracellular domain with 
10-12 cysteine residues, a single transmembrane domain and the intracellular 
serine/threonine kinase domain.  The BMP type 1 receptors include Activin receptor like 




kinases 1-7 (ALK1-7) and the type 2 receptors are BMPR2, ActR11b and  ActR11b [195].  
BMPR2 is specific for the activation of the BMP pathway.  ALKs are classified into three 
groups based on similarities in their structure and function. The BMPR-1 group includes 
ALK3 and 6, the ALK1 group includes ALK1 and 2, and the TβRI group includes ALK4, 
5 and 7 [175].   The ALK1 group of receptors activates Smad1/5/8 and transduces similar 
intracellular signals, while those of the TβRI group activate Smad 2/3. Type 2 receptors 
affect the specificity of BMP binding to type 1 receptors [197].  BMP2 and BMP4 
typically activate ALK3 and 6.  
Receptors bind with different affinities to individual BMPs.  Upon binding of the 
activated ligands to their receptor there is an increase in oligomerization of the receptors 
and possible conformational changes. When the activated ligand binds the constitutively 
active type 2 receptor, the type 2 receptor phosphorylates the type 1 receptor in its 
glycine and serine-rich domain [198].  This phosphorylation activates the type 1 receptor 









Figure	  4.	  	  The	  activation	  of	  BMP	  target	  genes	  through	  the	  BMP	  pathway	  
Balemans and Van Hul, Developmental Biology, 2002 [199] 
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The L45 region in the kinase domain of the activated type 1 receptor 
phosphorylates the receptor-regulated R-Smads, Smad1, Smad5 or Smad8 in the 
cytoplasm.  The phospho-R-Smad then complexes with the common Smad, co-Smad4.  
This R-Smad/Smad 4 complex moves to the nucleus where it binds to regulatory regions 
of target genes [200] (Figure 4). BMPs are capable of activating non-Smad pathways 
such as the Phosphoinosotide-3-Kinase [201, 202], however, for our purpose we will 
focus on the Smad dependent pathway. 
 
BMP	  and	  cancer	  	  
BMP plays a key role in the growth of gastrointestinal, epithelial and 
developmental cancers [203]. Depletion of  BMPR2 by RNA interference in mice  
resulted in gastrointestinal hyperplasia as well as dysmorphogenesis and predisposition to 
angio-proliferative diseases [204]. Conditional inactivation of BMPR2 leads to colorectal 
epithelial overgrowth and polyp formation [205]. Mutations in ALK3 as well as Smad4 
have been found in some patients with autosomal dominant syndrome juvenile polyposis, 
an autosomal dominant disorder caused by these mutations [206].   
 
Regulation	  of	  the	  Id1	  promoter	  by	  the	  BMP	  pathway	  	  
In 1999 the Id genes were identified as direct targets of BMP [207].  Id1-3 were 
activated by BMP4 in a number of cell lines.  This activation was very rapid and 
independent of new protein synthesis.  In addition, actinomycin D inhibited this response. 
This indicates that the induction of the Id genes by BMP4 is regulated at the 
transcriptional level [207].  In the years following many researchers studied the role of 




BMP on Id1 activation.  In 2002 for example, Valdimarsdottir et al. demonstrated that 
Id1 stimulation by BMP is necessary and sufficient for BMP induced activation of 
endothelial cells [208].  BMP2 also enhances the expression of Id1 in osteoblastic cells 
[209].  
Katagiri et al. demonstrated that BMP2 activates Id1 gene expression within an 
hour of BMP2 treatment during the differentiation of C2C12 myoblasts into osteoblasts.   
In 2002 three groups identified a BMP responsive element in the Id1 promoter.  Katagiri 
et al.[210] identified a 29 bp GC rich element between -985 and -957 of the human Id1 
promoter as a BRE.  This was identified in C2C12 myoblastic cells. They found that -985 
to -957 of the human Id1 promoter was necessary for Id1 activation by BMP2.  This 
region showed homology to the mouse Id1 promoter in a region identified by Tournay 
and Benezra [127] as an Id1 expression element, which contains an Egr1 binding site 





Figure 5.  Sequence similarity between the hId1 and mId1 promoter. 
Egr1 and M8 are sites identified by Tournay and Benezra. M8 is a GC rich region 
identified in [127] as being important in Id1 serum expression. * indicates a difference in 
the human and mouse promoter nucleotide sequence. The blue box shows the 29 bp BRE.  
 
The 29 bp region was both necessary and sufficient for BMP2 induction. Taken together 
this group identified a BRE in the hId1 promoter.  The BRE encompasses the Egr1 
binding site [210].  
Around the same time another group identified a BRE in the mouse Id1 promoter 














Figure 6.  100 bp conserved region of Id1.   
Known consensus sites for binding factors. The blue box is the BRE in [29] while the red 
box is the element identified by Katagiri et al [210].  The green boxes represent the SBEs, 
which are necessary for Id1 expression. M8 is a GC rich region identified in [127] as 
being important in Id1 serum expression. M16/M17 was also identified as an important in 
serum regulation of Id1 [127].   
 
increased in C2C12 muscle cells by treatment with BMP2, BMP6 and BMP7.   This 
increased expression was an IEG response that was transcriptionally regulated. The 
mouse and human Id1 promoters were activated by BMP2, BMP4, BMP6, and BMP7. 
This response was mapped to two regions of the Id1 promoter; one contains two SBEs 
and the other a palandromic sequence, GGCGCC.  The BRE was located between -1133 
and -1070 of the mouse Id1 promoter.  This overlaps the region identified by Katagiri et 
al. [210] (Figure 6).  This group also showed that the Smad4 binding motifs CAGC and 
CGCC are needed for optimal Id1 expression. One of these elements was located in the 
M16-M17 region that was previously identified as critical for Id1 serum expression [127] 
(Figure 6).  None of the elements was sufficient for Id1 expression suggesting that they 
work together. Yet another group identified the same region, in addition to downstream 
SBEs as important for Id1 promoter regulation by BMPs [164].  These groups show that 
the GC rich/Egr1 binding region and several SBEs are important for Id1 expression.  
However, it was not clear which is the key element.   
The coordinated expression of the Id family by factors was suggested after a 
common BRE was proposed in the Id family [211]. Two groups later discovered BREs in 
Id2 [212] and Id3 [213] which are necessary for BMP induction of these genes.  An 
element similar to the element identified in Id3 is in the same region as the M16-M17 and 
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SBE region identified by Tournay et al [127]. This region is well conserved between 
species and among the Id family members. This indicates that the M16-M17 and SBE 
regions may be very important for Id1 regulation.   
In 2012, Kurooka et al. [214] showed that Id2 is inducible by BMP2 through the 
BRE in its promoter.  They showed that BMP2 in serum is responsible for the serum 
regulation of the Id2 gene.  This BRE is identical to the one identified in Id3 that is 
critical for BMP induction and is in the M16-M17 and SBE region. The element 
responsible for serum regulation of the Id1 gene was not identified. 
 
Id1	  and	  Cancer	  	  
  The first evidence of Id1’s involvement in cancer came in 1991 when Alani et al. [215] 
demonstrated that overexpression Id1 in human keratinocytes resulted in induction of cell 
proliferation, inhibition of cellular senescence and differentiation, prolonged life span and 
eventually immortalization.  Telomerase activity in these cells was activated.   These are 
some hallmarks of cancer, therefore, Id1 was implicated in tumorigenesis. Subsequently,  
Id1 deregulation has been observed in many kinds of cancer including ovarian [216, 217], 
colon [218], breast [219, 220], thyroid [221, 222] and other cancers.  Although Id1 is 
involved in many areas of tumorigenesis (Figure 8), I briefly will discuss its involvement 
in two key steps of tumorigenesis, namely metastasis and angiogenesis. 
 
Id1 in tumor metastasis      
Tumor invasion involves invasion of the tumor into adjacent or distal sites. This results in 
metastasis.  One important step in metastasis is the dissolution of the Extra Cellular 




Matrix (ECM).  A family of matrix metalloproteinases is important in the regulation of 
ECM degradation [223] and cancer progression . Id1 is often upregulated in cancers [224]. 
Desprez et al. found that constitutive expression of Id1 resulted in the upregulation of a 
MMP protein [225]. It’s also been demonstrated that Id1 is one of the key regulators of 
breast cancer metastasis [226]. Id1 plays a role in epithelial mesenchymal transition 
(EMT) [227].  EMT is critical for metastasis, which is one of the reasons why people die 
from cancer.  
 
Id1 in angiogenesis 
Angiogenesis provides the blood supply necessary during the growth of the tumor and 
during metastasis. Many factors such as HIF [228] and VEGF [229] are involved in this 
process.  Studies in knockout mice showed that Id1 expression is essential for 
angiogenesis during tumor progression [230].  Loss of capillary branching was observed 
in Id1/Id3 double knockout mice. VEGF was downregulated in the endothelial cells of 
the knock out mice.  VEGF has been identified as a downstream target of Id1 [231].  It 
has also been observed that Id 1confers angiogenic properties on fully differentiated 
endothelial cells, contributes to therapeutic angiogenesis [232] and vascularization of 
tumor xenographs [230]. Id1 expression can be used to mark endothelial progenitor cells 
that are critical to tumor growth and angiogenesis [230, 233]. 
Following is a survey of the other areas of Id1 involvement in tumorigenesis: 
 Id1 promotes lung cancer growth in a BMP2, Smad 1/5 dependent manner [234].   Id1 
has been proposed as a molecular target in breast cancer [235] and ovarian cancer [236]. Id1	  can	  localize to centrosomes and induce abnormal centrosome numbers in human 




primary cells and tumor cell lines [237]. Id1 protein is required for BCR/ABL-mediated 
leukemogenesis [238]. Id1 is necessary to confer self-renewal capacity of cancer stem 
cells [218, 239].  All of these lines of evidence show that Id1 plays varying roles in 
carcinogenesis.  In fact the high expression of Id1 in cancer has been associated with poor 






Involvement	  of	  Id1	  in	  cancer.	  Id1	  is	  involved	  many	  processes	  important	  in	  the	  biology	  of	  cancer	  formation.	  	  	  
	  
	  
We have found that the serum induction of Id1 is independent of SRF, the MAP 
kinase and the PI3 Kinase pathways.  Therefore, we predicted that Id1’s serum regulation 
is modulated through a novel serum pathway. Here we show that a previously identified 
element [29, 127] in the Id1 promoter is necessary and sufficient for serum regulation of 




the Id1 promoter in NIH3T3 cells. We also demonstrate that the Src kinase inhibitor 
AZD0530 directly inhibits the BMP type 1 receptors and serum induced Id1 expression. 
AZD0530 treatment decreases the expression of Id1 in the colon cancer cell line HCT116 
in a phospho-Smad1/5/8 dependent manner.   	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Immediate Early Genes (IEGs) are expressed upon re-entry of quiescent cells into the cell 
cycle following serum stimulation.  These genes are involved in growth control and 
differentiation and hence their expression is tightly controlled.  Many IEGs are regulated 
through Serum Response Elements (SREs) in their promoters, which bind Serum 
Response Factor (SRF).   However, many other IEGs do not have SREs in their 
promoters and their serum regulation is poorly understood.   
 
Results 
We have identified SRF independent IEGs in SRF-depleted fibroblasts. One of these, Id1, 
was examined more closely. We have mapped a serum responsive element in the Id1 
promoter and find that it is identical to a BMP Responsive Element (BRE).  The Id1 BRE 
is necessary and sufficient for the serum regulation of Id1.  Inhibition of the BMP 
pathway by siRNA depletion of Smad 4, treatment with the BMP receptor antagonist 
noggin, or treatment with the BMP receptor inhibitor dorsomorphin all blocked serum 
induction of Id1. Further, BMP2 is sufficient to induce Id1 expression. Given reports that 
Src inhibitors can block Id1 expression, we tested the Src inhibitor, AZD0530, and found 
that it inhibits the serum activation of Id1.  Surprisingly, this inhibition is independent of 









Serum induction of the Id1 gene required the BMP pathway from BMP receptors to 
binding of Smads to BREs in the Id1 promoter.  The Id family of IEGs is regulated by 
BMPs in serum through similar BREs.   This represents a second pathway for serum 
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When growth factors are removed from NIH3T3 mouse fibroblasts they become 
quiescent.  Upon re-stimulation with serum or specific growth factors, these cells re-enter 
the cell cycle.  A class of genes, Immediate Early Genes (IEGs), is expressed rapidly and 
transiently upon treatment with serum or growth factors [10-13, 241]. The expression of 
these genes is independent of new protein synthesis, suggesting that is it is a relatively 
direct response to serum induction.  IEGs are involved in a plethora of processes 
including growth [17], differentiation, lineage determination, learning and memory [21]. 
c-fos, c-jun and c-myc are among the earliest and most well studied IEGs. The regulation 
of these IEGs is tightly controlled, and misregulation can lead to many diseases including 
cancer, neurological disorders [24] bone remodeling disorders [25]  and other chronic 
diseases.  As reviewed in Dunn et al. [26], IEG expression in many cancers is found to be 
sustained and abnormally high.  Understanding the transcriptional regulation of IEGs is 
an important step in understanding how their deregulation results in disease and finding 
better therapies to counter them. 
Hundreds of experimentally validated or hypothesized genes have a Serum 
Response Element (SRE) or CArG box in their promoter region [27-30].  The MADS box 
family member, Serum Response Factor (SRF), binds to the SREs of these genes [24, 41, 
42, 46]. SRF is constitutively present at the promoters of the genes it regulates [57].  
When quiescent cells are stimulated with the growth factors in serum, two pathways 
sufficient for SRE activation are activated, the mitogen activated protein kinase (MAPK; 
ERK1/2) and the RhoA GTPase pathways. The MAPK pathway, through a cascade of 
factors, leads to the phosphorylation and activation of SRF co-factors, the ternary 




complex factors (TCFs) Elk1, Sap1 and Net [22, 58].  SRF is also activated by the small 
GTPase RhoA via another group of SRF co-transcriptional activators, the myocardin 
related factors, Megakaryoblastic Leukemia 1/2 (MKL1/2) [59-62].  RhoA activation 
leads to changes in the actin cytoskeleton, which directly results in changes in the nuclear 
localization and activation of MKL1/2 and therefore activation of SRF target gene 
expression [90, 92-94, 242].  
Some IEGs do not have clear SREs in their promoters. Their induction may be 
due to cryptic or distant SREs or entirely different pathways. As described here, some 
IEGs do not require SRF for their serum induction. It would be interesting to find out 
whether there is another common sequence element or pathway through which these 
SRE-lacking, SRF-independent IEGs are regulated.   Inhibitor of DNA 
binding/differentiation 1 (Id1) is a member of this group.   
Id1 is a member of the Helix Loop Helix (HLH) family of transcription factors 
[121, 128], which form heterodimers with other members of the HLH family.  The Id1 
protein lacks a basic DNA-binding domain but is still able to form heterodimers with 
other HLH proteins that contain basic domains (bHLH proteins) [132]. These 
heterodimers are unable to bind DNA, thereby inhibiting the transcriptional activity of 
the bHLH proteins. 
Id1 is ubiquitously expressed [134] and is regulated by the TGF-β super-family of 
transcription factors.  Id1 expression is increased by prolonged exposure to TGF-β1 in 
human epithelial cells [146].  Smad3 and ATF binding elements in the Id1 promoter 
mediate this regulation.   Id1 is also activated by TGF-β1 in the human mammary gland 
cell line, MCF10A [147]. Smad3 also mediates this regulation.   Several groups have 




shown that Id1 expression is also increased in response to BMP signaling [152-155].   
Sequences in the Id1 promoter responsible for BMP activation were mapped to two close 
but distinct regions [29, 172, 210].  Subsequently, common BMP responsive sequences 
were found for the Id family of genes in Xenopus (TGGCGCCAG-N3-GTCTG) that were 
conserved in mammals [169]. The element mutated by Korchynskyi et al. partially 
matches this consensus [29]. We refer to this sequence at -1067 to -1050 in the mouse Id1 
promoter as the BMP responsive element (BRE). Overall expression of Id1 was shown to 
be regulated by an Egr-1 binding site upstream of the BRE [127]. Expression of Id1 in 
cells grown continually in serum-containing media vs. low serum media was reduced by 
mutations (m16 and m17) in the BRE region, however it was not clear what factors or 
pathways activated through this element [127]. It was also not clear whether rapid serum 
induction acted through this region.  
BMP is a member of the TGFβ family of transcription factors.  Upon activation of 
BMPs, they bind to their transmembrane type I and type II receptors [195]. These 
receptors encode serine/threonine kinases.  The activated type 1 receptor phosphorylates 
the receptor-regulated R-Smads, Smad1, Smad5 and Smad8 in the cytoplasm. The 
phospho-R-Smad then complexes with the common Smad, Smad4. This R-Smad/Smad 4 
complex moves to the nucleus where it binds to regulatory regions of target genes [200].  
Here we show that a previously identified element [29, 127] in the Id1 promoter is a 
BMP responsive element and is also necessary and sufficient for serum regulation of the 
Id1 promoter in NIH3T3 cells. 
 Id genes are required for G1 progression and regulate cellular senescence [143].   
Deregulation of Id1 expression is observed in many kinds of cancer including ovarian 




[216, 217], colon [218], breast [219, 220], and thyroid [221, 222] cancers. Id1 promotes 
migration and proliferation of cancer cells in vitro [243, 244], confers angiogenic 
properties on fully differentiated endothelial cells, contributes to therapeutic angiogenesis 
[232] and is required for angiogenesis [245], neurogenesis and vascularization of tumor 
xenographs [230].  Further, it has been demonstrated that Id1 promotes lung cancer 
growth in a BMP2, Smad1/5 dependent manner [234].  Id1 has been proposed as a 
molecular target in breast and ovarian cancers [235, 246].  Here we demonstrate that the 
src kinase inhibitor, saracatinib (AZD0530), directly inhibits the BMP type 1 receptors 
and is able to reduce the phosphorylation of Smad1/5/8  and the expression of Id1 in the 
colon cancer cell line HCT116.  Therefore, this and other drugs that inhibit the BMP 
receptors may have therapeutic potential in cancers, which have perturbed BMP signaling, 

















Serum	  induction	  of	  Id1	  is	  independent	  of	  SRF	  	  
In order to identify IEGs whose expression was independent of SRF we made 
stable cell lines expressing shRNA lentiviral vectors that target SRF in NIH3T3 mouse 
fibroblasts.   The expression of SRF was significantly decreased in two clones (shSRF-1 
and shSRF-2), decreasing SRF mRNA expression by at least 70% at all time points of 
serum induction (Fig. 1B). The decrease in expression was stronger at the protein level 
(Fig. 1A) with stronger reduction of SRF in shSRF-2.   NIH3T3 cells containing shRNA 
that does not target any known mouse gene was used as the control cell line. We analyzed 
the serum regulation of many IEGs in NIH3T3 cells induced with serum for 0 to 2 hours 
following overnight serum starvation.   The transcript levels of 19 IEGs that were 
previously identified in NIH3T3 cells [30] were measured by quantitative RT-PCR 
(qPCR). Not surprisingly, the serum regulation of many IEGs such as CTGF, egr-2, and 
nur77 were SRF dependent while others such as Id1, Id3 and mig6 were SRF 
independent (Fig. 1B and supplemental figure 1).  Surprisingly the expression of c-fos, 
the longest studied SRF target gene, was only slightly affected.  This may be because 
residual SRF was sufficient to facilitate c-fos expression or that there is another 
mechanism by which c-fos can be serum regulated (see Discussion).  cyr61 induction also 
appeared SRF-independent, despite previous mapping of SREs in its promoter [36]. As 
with c-fos, it may only require low levels of SRF or use a different mechanism. Other 
genes with previously reported SREs, such as vcl, nur77, and egr2 were in-fact SRF 
dependent (Figs. 1 and S1 and supplemental table 1.) 




  While, the level of SRF expression is significantly reduced by use of shRNAs 
targeting SRF, the residual SRF mRNA is still serum inducible (Fig. 1B).    This is not 
surprising as SRF itself is an IEG.  In SRF depleted cells, however, many of the genes 
appeared SRF-independent. (Fig. 1, Fig. S1 & supplemental table 1). Of these, the serum 
induction of Id1 actually increased upon depletion of SRF at the 30 and 60-minute time 
points (Fig. 1B). This and the lack of putative SREs in the Id1 gene suggest that Id1 
induction is SRF-independent. Consequently, we proceeded to identify sequence 
elements and factors responsible for the serum regulation of the Id1 IEG. 
 
Serum	  induction	  of	  Id1	  does	  not	  require	  the	  PI3K	  or	  the	  MAPK	  pathway	  	  
SRF target genes are regulated through the RhoA or MAPK pathways.  We 
studied whether these or other known pathways are involved in serum regulation of Id1 
by utilizing pathway inhibitors.    The serum induction of Id1 was assayed in the presence 
and absence of phosphoinositide-3-kinase (PI3K) inhibitor LY294002 and MAPK 
pathway MEK1 inhibitor, PD0325901. NIH3T3 cells were pretreated for 1 hour with 
either LY294002 or PD0325901, followed by serum induction for 0 to 120 minutes.  The 
potency of the drugs was confirmed by immunoblotting for phospho-AKT and phospho-
ERK1/2, respectively (Fig. 2). The RNA levels of Id1 were unchanged when treated with 
the inhibitors (Figs. 2A and B). The need for ERK1/2 in c-fos serum regulation is well 
documented, at least partially due to the phosphorylation of the ELK1 family members 
[241].   Not surprising, c-fos expression was dramatically decreased when NIH3T3 cells 
were treated with PD0325901, while treating the cells with LY294002 had little effect on 
c-fos expression (Fig. 2).  To study the RhoA pathway we utilized the RhoA inhibitor, C3 




transferase [247], using the Id1 reporter gene as described below. There was no effect on 
Id1 promoter activation by serum while c-fos promoter activation was inhibited in the 
presence of a C3 transferase expression vector (data not shown).  These results suggest 
that Id1 serum regulation does not require the ERK1/2, RhoA nor PI3K pathways. 
 
Mapping	  of	  sequence	  elements	  responsible	  for	  serum	  induction	  of	  Id1	  	  
In order to decipher the factor(s) and pathway(s) involved in the serum regulation 
of Id1, promoter mapping of the mouse Id1 promoter was undertaken in NIH3T3 cells.   
We found that a construct containing -1577 to +54 of the mouse Id1 gene was sufficient 
to mediate nearly a 5 fold serum-induced increase in luciferase expression (Fig. 3A, B). 
A series of deletion constructs were made between -1577 and -1050 of the mId1 promoter 
(Fig. 3A). This allowed us to map a region required for serum activation to a 100 bp 
region between -1150 and -1050 (Fig. 3B).  This region of the promoter is particularly 
conserved as shown by the alignment of the mouse, human and chicken Id1 promoters 
(Fig. 3C).  Critical elements have previously been identified in this region for expression 
in cells grown in serum containing medium compared to cells starved for serum [127]. 
These and other studies identified binding sites for YY1, Egr1, CREB/ATF and a Smad 
binding element (SBE). In addition, systematic point mutation identified the M8 and 
M16/M17 regions as being required for expression [127].  In order to identify the 
sequence element(s) important for serum regulation of the Id1 promoter, a series of 
mutations was made in this 100bp region of Id1 (Fig. 4A, B). Mutation of most of the 
known sites had some effect, but also retained some serum induction (Fig. 4D).  The most 
striking difference was observed with mutation of the M16/M17 region (mBRE; Fig. 4D).  




This region was previously identified as a Smad responsive element [29] and is similar to 
regions in the Id2 and Id3 promoters required for BMP induction [213, 214] (Fig. 4C). 
We will therefore refer to it as a BMP Response Element (BRE).   We made finer 
mutations across the BRE and found that each reduced expression, except for those on 
the downstream part of the site that overlap the spacer region of the consensus sequence 
(mBRE-R-b; Fig. 4E). Other mutations in the element (BRE-L and BRE-R) showed that 
the consensus region is needed for optimal Id1 serum induction (Fig. 4E).    
The conserved region of -1150 to -1050 was sufficient to mediate serum induction 
when placed upstream of an SV40 promoter (Fig. 5B). However, a single copy of the 
BRE was not sufficient, as a -1177 to -1050 construct (that lacks the YY1-Egr1-GC 
region) did not mediate serum induction. When four copies of the BRE were placed in 
front of the SV40 promoter, there was basal expression but it was not inducible by serum 
(Fig. 5).  While the SBE region was also not sufficient, the combination of the BRE and 
SBE was sufficient for serum induction.  This is not surprising as the BRE-SBE 
combination is conserved in the Id1, 2 and 3 genes (Fig. 4C) and the sequence matches 
the sequence which is thought to be important for the binding of the co-Smad, Smad4 
[158] .   It is likely that while the R-Smads bind the BRE, the SBE is bound by co-Smad4.  
Our efforts to show specific Smad binding in this region of DNA were unsuccessful.   We 
and others have seen weak specific binding of a factor in the BRE – SBE region by 
electrophoretic mobility shift assays (EMSA) (unpublished results and [127]), but we 
were unable to successfully identify the factor(s) which, bind this region. Nevertheless, 
given previous analysis of Smad binding to BRE sequences, it is likely that Smad4 binds 
with Smad1, 5 or 8 [158, 214].   




It has been reported that bovine serum contains a BMP-like factor [248]. This and 
the requirement of the BRE sequence suggest that the BMP-Smad pathway is mediating 
serum induction of Id1 expression. To further test this model, we utilized purified BMP2 
and known inhibitors of the BMP pathway. BMP2 induced Id1 expression in NIH3T3 
cells about twice as strongly as serum (Fig. 6A), confirming that the BMP pathway is 
sufficient for induction of Id1 and that there are receptors for BMP2 on NIH3T3 cells. 
BMP2 was also able to activate the Id1 promoter similar to serum in a reporter assay (Fig. 
6B). Not surprisingly, serum and BMP2 both induced the phosphorylation of Smad1/5/8 
in starved NIH3T3 cells (Fig 6C). We also used the BMP receptor antagonist noggin to 
study its effect on Id1 serum induction. Noggin-treatment of NIH3T3 cells abolished 
serum induction of Id1 (Fig. 6A).  Noggin also abolished serum activation of the Id1 
promoter in a reporter assay (Fig. 6B). This was confirmed by the use of the small 
molecule inhibitor, dorsomorphin, which is a known inhibitor of BMP receptors [249]. 
Dorsomorphin strongly inhibited induction of Id1 mRNA in response to serum treatment 
(Fig. 6D). Finally, we depleted NIH3T3 cells of the co-Smad regulator, Smad4, with 
siRNAs.  Smad4 mRNA was reduced at least 80% by the siRNAs. This strongly impaired 
serum induction of Id1 mRNA (Fig. 6E). Therefore, these experiments show that the 
BMP pathway is indispensable for serum induction of Id1.   
 
The	  src	  inhibitor	  AZD0530	  inhibits	  Id1	  expression	  	  
We were prompted to examine the possibility of the tyrosine kinase Src’s 
involvement in Id1 regulation as the Src inhibitor AZD0530 (sarcatinib) was found to 
inhibit Id1 expression in the A549 lung carcinoma cell line, while the Src inhibitor PP2 




inhibited Id1 expression in the MDA-MB-231 breast carcinoma line [154, 250]. 
AZD0530 inhibited Id1 expression while preventing activation of Smad1/5 [154]. We 
investigated whether AZD0530 inhibits the serum induction of Id1.  NIH3T3 cells 
pretreated with AZD0530 showed a complete loss of Id1 serum induction both in mRNA 
expression and promoter activation (Fig. 7A and B). Induction of both the longer -1150 
Id1 reporter and the shorter 4X BRE-SBE reporter were blocked by AZD0530, while as a 
control, there was little effect on induction of the c-fos promoter (Fig. 7B). We tested for 
AZD0530 sensitivity on other IEG expression. Id3 was strongly reduced (Fig. 7A), 
consistent with it containing a BRE-like sequence [213].  There was no effect on c-fos 
induction (Fig. 7A). The IEG, PAI-1, on the other hand, showed a decrease in serum 
activation, suggesting that it is partially regulated by an AZD0530 sensitive pathway, 
similar to Id1.  
Surprisingly, the serum-induced autophosphorylation of Src at Tyrosine 416 was 
unaffected at the concentration of AZD0530 that inhibited Id1 expression (Fig. 8A).  We 
sought to further examine whether src family members are involved in Id1 serum 
regulation.  Neither another Src inhibitor, PP2, nor the BCR-abl inhibitor, imatinib, had 
any effect on the response of the Id1 gene to serum (data not shown).  In addition, we 
tested SYF cells, which are fibroblasts deficient in the expression of src family members 
src, yes, and fyn [251]. Serum induction of Id1 was normal in the SYF null cells and 
there was actually higher serum induction of Id3 in these cells (Figure 8B). src, yes and 
fyn are the three predominant Src family members expressed in fibroblasts, though it is 
possible that low expression of other family members could be involved in Id1 regulation.  
However, since Src phosphorylation was not affected by AZD0530, since loss of the 




three Src family members had no effect, and since other src inhibitors did not block Id1 
expression, we considered the possibility that AZD0530 was inhibiting Id1 expression 
through another mechanism. 
 Since earlier studies have shown that Smad1/5/8 are involved in Id1 expression 
and that these Smads are necessary for BMP signaling [152, 154], we studied whether 
treating NIH3T3 cells with AZD0530 affects the phosphorylation status of these Smads. 
AZD0530 blocked the phosphorylation of phospho-Smad1/5/8 suggesting that it blocks a 
component upstream of Smad1/5/8 phosphorylation (Fig. 8A). The total level of 
Smad1/5/8 was not affected by treatment with AZD0530 (data not shown).  As a control, 
there was no effect on phospho-ERK1/2 induction.   
One possibility is that AZD0530 directly inhibits the activity of BMP receptors 
involved in BMP signaling.  We tested this hypothesis by testing the inhibition of BMP 
receptor kinase activity by AZD0530 in vitro. The BMP family of receptors consists of 
two subunits. The type 2 receptor is common, BMPR-2, while there are seven type 1 
receptors, termed ALK1 to 7 [182, 184, 195]. There was no inhibition of BMPR-2 kinase 
activity in vitro, however there was strong inhibition of ALK1, 2, and 3 with IC50 values 
in the 3-30 nM range (Fig. 9).  Inhibition of ALK4, 5 and 6 was less sensitive, with IC50s 
in the 300-800 nM range.  For comparison, inhibition by a non-specific protein kinase 
inhibitor, staurosponine, varied, but was closer to the micromolar range (Fig. 9B). ALK1, 
2 and 3 are receptor subunits for the BMP family members BMP2, 4 and 6, which can 
each activate Id1 [159, 252]. 
We sought to confirm this inhibition of BMP receptors by AZD0530 in vivo using 
a reporter assay. We transfected constitutively active forms of each of the BMP receptors 




[29, 253] with the Id1 reporter gene. We found that the BMP responsive ALKs, ALK1, 2 
and 3 activated the Id1 promoter in the absence of serum, while there was no activation 
by ALK4, 5 and 7  (Fig. 10).  The activation by ALK1, 2 and 3 was significantly 
decreased in the presence of AZD0530.  The limited inhibition compared to that with 
rapid serum induction may have to do with the long-term transfection of the 
constitutively activated receptors. It is also possible that AZD0530 is less effective at 
inhibiting the constitutively activated forms compared to the normal forms of these 
proteins.  
Finally we sought to check the efficacy of AZD0530 in blocking Id1 expression 
in a colon cancer cell line, HCT116, which exhibits high Id1 expression.   We found that 
Id1 expression and Smad1/5/8 phosphorylation were constitutively elevated in these cells 
(Fig. 11A and B).  Upon starvation of HCT116 cells and serum stimulation, there was 
some further increase in phospho-Smad1/5/8 levels, but there was no further increase in 
Id1 expression, demonstrating that Id1 expression is misregulated in these cells. 
Treatment with AZD0530 or dorsomorphin resulted in the inhibition of phospho-
Smad1/5/8 levels as well as inhibition of Id1 expression. These results show that 
AZD0530 can be used to reduce Id1 levels in cancer cells and suggest that altered Id1 







 	  	  






There are many IEGs that do not have clear SREs in their promoters.   Whether 
there is a common pathway/DNA element by which some of these genes are regulated by 
serum is yet unknown.  We sought to identify genes which do not contain SREs and 
whose serum regulation is independent of SRF.   Many SRE containing genes were found 
to be SRF dependent.   Unexpectedly c-fos, the canonical SRF regulated gene, was not 
SRF dependent.  This may indicate that the residual SRF is sufficient to allow c-fos 
induction.  SRF binding to the c-fos SRE in the SRF depleted cells was reduced by 50-
70% in chromatin immunoprecipitation assays such that this residual binding may be 
sufficient for induction (unpublished results). It is possible that due to the different 
affinities of SREs for SRF that certain IEGs, such as c-fos, require less SRF. 
Alternatively, there may be another pathway for c-fos induction in NIH3T3 cells. Loss of 
the SRF alleles in ES cells resulted in a strong reduction of serum-induced c-fos 
expression [56].  However, there was low residual serum induction in these cells, 
supporting the existence of an alternative pathway. Understanding whether there is a 
lower SRF threshold or an alternative pathway for c-fos regulation will be important.   
We found that the serum regulation of Id1 and Id3, members of the HLH group of 
transcription factors, was independent of SRF.   The serum induction of Id1 and Id3 both 
increased when SRF was depleted by shRNAs and was independent of the ERK1/2, 
RhoA and PI3K pathways. This suggests that there is a novel pathway through which 
these genes are regulated by serum as SRF. Many IEGs are regulated by one or more of 
these pathways [60, 241].  In addition, there are no SRE sequences found in the Id1 




promoter and no SRF binding was observed in genomic chromatin immunoprecipitation 
experiments [254, 255]. 
We subsequently identified a BRE in the promoter of Id1 as being responsible for 
its serum activation. Although the element in Id1 was identified previously [29, 210], its 
link to serum activation of Id1 was unknown.  A BRE is a GC rich sequence, i.e. 
GCCGNC or GRCGNC to which BMP responsive Smads bind [164, 165, 256].  It also 
pairs with a Smad4 binding element (SBE)(GTCT) with a spacer of five bases between 
the sites (Fig.  4C; [257]). These BMP responsive elements are found in BMP target 
genes such as Id1 [29], Id2 [214] and Id3 [213].   BREs have been identified across the 
phylogenetic spectrum, found for example in Drosophila, Xenopus and mammals [258].  
We were able to show that the BRE-SBE element is necessary and sufficient for 
the serum activation of Id1. This BRE located at -1073 to -1056 in the mId1 promoter, is 
located within a highly conserved 100 bp region, -1150 to -1050.  Although many other 
transcription factors bind to the Id1 promoter within this 100 bp region, mutation of the 
BRE had the greatest effect on serum activation of the Id1 promoter.  It is quite 
conceivable that the BRE works with other sequences to obtain optimal serum induction. 
There were partial effects on Id1 expression when most of these sequences were mutated. 
Considerable evidence supports the serum activation of Id1 through the BMP pathway 
and the BRE.  The mId1 promoter was activated by BMP2, inhibited by the BMP 
receptor antagonist noggin, and blocked by the BMP receptor inhibitor dorsomorphin. 
We show that the BMP receptor inhibitor dorsomorphin inhibits the phosphorylation of 
Smad1/5/8 in NIH3T3 cells while the total level of Smad1/5/8 was unchanged.  Depleting 
the co-Smad, Smad4, also resulted in decreased activation of Id1.  These results 




confirmed the involvement of Smads and BMP in serum induced Id1 expression. 
Recently, it was shown that BMP signaling is also required for serum induction of the Id2 
gene [214]. It will be interesting to determine whether the BMP pathway also activates 
other IEGs. We found strong dependence with the Id3 gene and partial dependence with 
the PAI-1 gene, but no requirement with the other SRF-independent genes tested. 
AD0530 is a well-documented inhibitor of the Src family.  As reported previously 
[154], the treatment of NIH3T3 cells with AZD0530 caused a dramatic decrease in 
serum-induced Id1 expression.  However, we found that AZD0530 under our conditions 
(a lower concentration and briefer incubation) did not block Src phosphorylation at a site 
thought to be due to autophosphorylation. In addition, serum induction of Id1 was 
unaffected in SYF cells, which lack the three most abundant Src family members, src, yes 
and fyn. On the other hand, we found that AZD0530 specifically blocked serum induced 
Id1 expression, Id1 reporter gene expression and Smad1/5/8 phosphorylation. In vitro 
kinase assays showed that AZD0530 directly inhibits the BMP type I receptors, ALK1, 2 
and 3. We confirmed inhibition of these ALKs in vivo by AZD0530 using constitutively 
activated forms of the receptors with the Id1 reporter genes. Together these experiments 
suggest that AZD0530 blocks activation of the Id1 promoter by direct inhibition of the 
BMP receptor subunit rather than by inhibition of the Src family. 
Increased Id family expression is a hallmark of many cancers [259-261] and Id1 
overexpression and BMP constitutive activation [246] is associated with tumor 
angiogenesis in human pancreatic [262] and other cancers [217, 263, 264].  As we have 
shown that the small molecule AZD0530 inhibits the serum induction of Id1 at low 




concentrations through inhibition of the BMP receptors, AZD0530 may have therapeutic 
potential in targeting this pathway in addition to its effects on Src.  
To check this hypothesis we looked in HCT116 colon cancer cells, which are 
known to have elevated levels of Id1 [265].  We found constitutive, serum-independent, 
expression of Id1 in these cells and high basal phospho-Smad1/5/8 levels. Treatment of 
these cells with AZD0530 or dorsomorphin blocked phosphorylation of Smad1/5/8 and 
expression of Id1.  These results suggest that AZD0530 may be a promising drug for 
treatment of cancers in which Id1 is constitutively active due to deregulation of the BMP 
pathway. 
 Finally, we propose a model of IEG activation in which members of the HLH family of 
transcription factors are activated by serum through the presence of BREs in their 
promoters.  When quiescent cells are treated with serum, BMPs in serum bind to and 
activate the BMP receptors.  This results in the phosphorylation of the BMP responsive 
R-Smads, Smad1/5/8, by the type 1 BMP receptors.  The R-Smads then recruit co-Smad 
4; they migrate to the nucleus, bind BREs in the Id promoter regions and activate 
transcription of these HLH family members





A novel pathway of serum induction involving BMP receptors and their 
downstream effectors, in particular Smads regulates the Id family of transcription factors. 
This identifies a novel way by which SRF-independent IEGs are regulated.  In addition, 
we found that AZD0530 is an inhibitor of BMP type 1 receptors.   This drug, currently 
used as a Src inhibitor, may also be useful as a BMP pathway inhibitor, suggesting 



































Cell culture.  SRF shRNA and control cell lines were generated by stable infection of 
NIH3T3 with lentiviral vectors (pLKO.1) containing short hairpin RNA (shRNA) 
directed to SRF; shSRF-1, 5’-GCCAGCAUUCACAGUCACCAAC- 3’ and shSRF-2, 5’ 
–GAUGGAGUUCAUCGACAACAA -3’; a non-targeting shRNA was used to 
generate the control cell line. The lentiviruses were made in Phoenix-ECO cells (ATCC 
CRL3214). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% New Born Calf serum (NCS) and 10 µg/ml puromycin (Invivogen). 
NIH3T3 cells were grown in 5% CO2 in DMEM supplemented with 10% NCS.  HCT116 
and SYF cells were grown in 5% CO2 in DMEM supplemented with 10% Fetal Bovine 
Serum (FBS).  
  
Luciferase assays. NIH3T3 (4 x 104 cells/well) cells were plated on 24 well plates.  The 
following day the media was changed to fresh 10% NCS in DMEM.  The cells were 
transfected with Polyjet reagent (Signagen), 100 ng of pRLSV40P (SV40 promoter 
driving the Renilla luciferase gene) and 100 ng of pGL3 Id1 or c-fos reporter genes.  For 
transfection with constitutively active BMP receptor genes, caALKs, 25 ng of each ALK 
was also transfected.  The next day the media was changed to DMEM containing 0.2 % 
NCS (starvation media).  For serum/BMP2 induction, the next day the cells were induced 
with 20% NCS or 20 ng/ml recombinant human BMP2 (Sino Biological Inc.) for 4 hours. 
The cells were harvested and luciferase activity assayed utilizing the Dual-Luciferase 
Reporter System (Promega). The Renilla luciferase activity was measured as an internal 
control and firefly luciferase values were normalized to the corresponding Renilla 
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luciferase levels.  For AZD0530 treatment, the cells were treated with 100 nM AZD0530 
(Selleck Chemicals) for 1 hour before the addition of serum. For noggin, 10 ng/ml noggin 
(STEMGENT) was added overnight while the cells were being starved in 0.2% NCS. 
  
siRNA treatment. Integrated DNA Technologies synthesized siRNA duplexes for 
mSmad4.  Two duplexes were used to deplete Smad4. Smad4-1 contains forward, 5’ - 
GCAAUUGAGAGUUUGGUAAAGAAGC-3’ and reverse 3’ – 
CUCGUUAACUCUCAAACCAUUUCUUCG - 5’.   Smad4-2 forward 5’- 
CAAAUACACCAACAAGUAACGAUGC and reverse 3’ – 
UUGUUUAUGUGGUUGUUCCAUUGCUACG – 3’. NIH3T3 cells (2 x 104 cells/well) 
were plated on 6 well plates. The next day, fresh media was added to each well. The cells 
were transfected with 50 pmoles siRNA using 3 µl Powerfect (Signagen) as per the 
company’s protocol.   The next day the media was changed to 0.2% NCS in DMEM. The 
cells were harvested in Tri Reagent (Molecular Research Center, Inc.) and mRNA levels 
determined as described below. 
  
Plasmids. The Id1 promoter fragments were cloned into the pGL3-basic plasmid utilizing 
restriction enzymes.   Mouse Id1 -1577 to +54 and -1050 to +54 were amplified from 
mouse genomic DNA (Bioline). All other deletion mutants were made utilizing Id1 -1577 
to +54 as a template.  Point mutations were made utilizing the QuikChange Multi Site-
Directed Mutagenesis Kit from Agilent in the mId1 -1150 background. The c-fos WT 
luciferase construct was as previously described [266] .The expression vector for 
constitutively active ALK1 pcDNA-ALK1 was a gift from Dr. Kristina Bostrom [253].  
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Expression vectors for constitutively active HA-ALK 2-5, 7 were gifts from Dr. Peter 
Ten Dijke [29]. 
  
Gene expression. mRNA expression levels were assayed by plating NIH3T3 cells on 6 
well plates; the next day the media was changed to 0.2% serum. The following day 
serum/BMP2 was added for the time indicated to a final concentration of 20% and 20 
ng/ml, respectively.   For LY294002, PD0325901, AZD0530 and Dorsomorphin 
treatment, the drugs were added one hour before addition of serum. 10 µm LY294002 
(ChemieTek), 5 µm PD0325901 (ChemieTek), 100 nM AZD0530 (Selleck Chemicals) or 
1 µm Dorsomorphin (Chemdea) were used. RNA was isolated using Tri Reagent 
(Molecular Research Center, Inc.) following the manufacturer’s instructions.   cDNA was 
made from 1 µg total RNA using ImProm-II reverse transcriptase (Promega) and random 
hexamer primers.  Individual gene expression was quantified with sybr green present in 
the Q-PCR master reaction mix (Thermo Scientific) and the Step One Plus machine 
(Applied Biosystems) was used for real time PCR quantification of gene expression. 18s 
rRNA expression was measured for normalization of all samples. Supplemental table S2 
shows the sequences of all the gene primers.  
 
Immunoblotting. Cells grown as described in preceding methods were rinsed twice in 
ice cold Phosphate Buffered Saline (PBS) and lysed in 1x passive lysis buffer from 
Promega.   Lysates were kept on ice for 20 minutes, then centrifuged at 11,000 X g for 20 
minutes at 4°C.  The samples were diluted with one half volume 3X protein sample 
buffer (188 mM Tris-Cl (pH 6.8), 3% SDS, 30% glycerol, 0.01% bromophenol blue, 15% 
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β-mercaptoethanol) and boiled for 5 minutes.  Proteins were separated by SDS-PAGE on 
10% or 12% polyacrylamide gels.  The proteins were transferred to a nitrocellulose 
membrane and the membrane was blocked in 6% nonfat dry milk for 1 hour, washed 3X 
in 1X Tris Buffered Saline (TBS) and incubated with primary antibody (1:1000) in TBS 
overnight at 4°C while shaking.  The next day the membrane was washed 3X with TBS-
tween (TBS, 0.1% tween-20).  The membrane was then incubated with fluorescently 
labeled secondary antibody (1:10,000) (IRDye goat anti rabbit 800 or goat anti rabbit 680 
or goat anti mouse 680; LI-COR Biosciences) for one hour at room temperature, washed 
twice with TBS-tween and once with TBS. The proteins were visualized using the Li-Cor 
Odyssey Infrared imaging system.  Primary antibodies against the proteins were as 
follows: Phospho-src Family (Tyr416) Antibody, rabbit, Cell Signaling; Total ERK 
(p44/42(ERK1/2) antibody, rabbit, Cell Signaling), Actin (1-19) Antibody, rabbit, Santa 
Cruz Biotechnology; SRF, rabbit, described in [267]; Phospho-Smad1/5/8 
(S463/S465/Smad8(S426/S428)) Antibody, rabbit, Cell Signaling;  Phospho (ERK) 
p44/42 MAP Kinase, rabbit, Cell Signaling; Phospho AKT (Thr 308) Antibody, rabbit, 
Cell Signaling. 
In vitro kinase reactions.  The Reaction Biology Corporation using the “HotSpot” assay 
platform performed the in vitro kinase reactions. Briefly, purified recombinant 
kinase/substrate pairs were incubated with the indicated concentrations of AZD0530 
(Selleck Chemicals) or Staurosporine and with a mixture of ATP (Sigma) and 33P-ATP to 
a final concentration of 10 µM in reaction buffer (20 mM Hepes pH 7.5, 10 mM MgCl2, 
1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% 
DMSO) for 120 minutes at 25 °C. The reactions were spotted onto P81 ion exchange 
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filter paper (Whatman) and free phosphate was removed by washing of filters in 0.75% 
phosphoric acid. The kinase activity data were expressed as the percent remaining kinase 
activity in test samples compared to vehicle (dimethyl sulfoxide) reactions. IC50 values 
and curve fits were obtained using Prism (GraphPad Software). 
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Figure	  Legends	  	  
Figure 1.  Effect of SRF depletion on the serum regulation of immediate early genes. 
A) SRF levels in NIH3T3 cells stably expressing control shRNA or shRNA targeting 
SRF were measured by immunoblotting with anti-SRF sera. Anti-ERK1/2  antibodies 
were used as a loading control. B) Control and SRF shRNA cells were starved in 0.2% 
serum overnight and then serum induced with 20% NCS for the indicated times. The 
levels of the indicated genes were measured using quantitative real time-PCR (Q-PCR) 
with 18s rRNA levels used to normalize the samples. The values are the means of three 
experiments +/- standard deviations.  
 
Figure 2. Inhibition of MAPK and PI3K signaling does not affect Id1 induction. 
A) NIH3T3 cells were grown overnight in 0.2% NCS, treated with the PI3K inhibitor 
LY294002 (10 µM) for 1 hour and then for 1 hour or the indicated times with 20% serum.  
Gene expression was analyzed by Q- PCR, as in figure 1. Phospho-ERK1/2 and phopho-
AKT levels were measured by immunoblotting with phospho-specific antibodies. B) 
Cells were treated for 1 hour with the MEK1 inhibitor, PD0325901, (5 µM for the RNA 
experiments and 1 or 5 µM, as indicated, for the immunoblots). The cells were then 
serum-stimulated, as described above, and measured by Q-PCR for mRNA expression 
and immunoblotting for ERK1/2 phosphorylation. Actin levels were measured by 
immunoblotting as a loading control.  
 
 




Figure 3.  Mapping the Serum regulation element of the mId1 promoter. 
A) Map of mouse Id1 promoter deletion mutants.  B) NIH3T3 cells were transfected with 
variants of the Id1 promoter along with pRLSV40P as an internal control. The next day 
transfected cells were starved in 0.2% serum overnight and then induced with 20% serum 
for four hours.  Firefly  luciferase levels were normalized to the Renilla pRLSV40P 
levels and are the means of three experiments  +/- the standard deviation. *** indicates a 
p-value ≤ 0.05. C) Conservation of sequence elements in the conserved 100 bp Id1 
promoter region -1150 to -1050. m, mouse; h, human; c, chicken. M8 and M16/M17 
indicated mutated regulatory elements from reference [127] . 
 
Figure 4.  Mapping the serum responsive element of the mId1 promoter.  
A) Sequence of the conserved regulatory region of mId1 with the indicated putative 
regulatory elements. B) Left (L), mutations in the BRE region and Right (R), mutations 
in the BRE region. C) Alignment of the BMP responsive elements (BRE) in the mouse 
Id1, Id2 and Id3 promoters. D, E) The indicated mutants were transfected into NIH3T3 
cells and assayed for luciferase activities as in figure 3.  
 
Figure 5.  The BRE-SBE elements are sufficient for serum induction. 
A) Four copies of the indicated elements of the mId1 promoter were cloned upstream of 
the SV40 promoter in the pGL3 luciferase reporter. B) These constructs were co-
transfected with pRLS40P into NIH 3T3 cells, serum-induced and assayed as in figure 3. 
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Figure 6.  The BMP pathway is necessary and sufficient for serum induction of Id1. 
A) NIH3T3 cells were serum-starved overnight and induced with 20% serum or 20 ng/ml 
BMP2 as indicated.  Where indicated, 100 ng/ml noggin was added during serum-
starvation. Gene expression was measured by Q-PCR as in figure 1.   B) NIH3T3 cells 
were transfected with the mId1 -1150 and pRLSV40P luciferase reporter constructs, 
serum starved with or without noggin, and induced with serum or BMP2 as in A. 
Luciferase levels were measured as in figure 3. C) NIH3T3 cells were starved in 0.2% 
serum overnight then induced with 20% serum or 20 ng/ml BMP2 for 1 hour.  The 
lysates were immunoblotted with phospho-Smad1/5/8 specific antibodies or anti-actin as 
a loading control.  D) NIH3T3 cells were serum-starved, treated with Dorsomorphin at 
the indicated concentrations for 1 hour, and then induced with 20% NCS for 1 hour. Id1 
mRNA levels were measured by Q-PCR as in figure 1. E) Cells were transfected with 
control or Smad4 siRNAs.  The next day the media was changed to 0.2% serum 
overnight and the cells serum-induced for 1 hour.   Smad4 and Id1 mRNA levels were 
measured by Q-PCR as in figure 1.  
 
Figure 7. src inhibitor AZD0530 inhibits serum induction of Id1. 
A) NIH3T3 cells were starved in 0.2% serum overnight and AZD0530 (100 nM) was 
added to the cells for 1 hour.  Cells were then induced with 20% serum for the indicated 
times. Gene expression of indicated genes was analyzed by Q-PCR as in figure 1. B) The 
indicated luciferase reporters (described in figures 3 and 5) as well as a c-fos promoter 
reporter were transfected into NIH3T3 cells as in figure 3.  The cells were treated with 
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AZD0530 (100 nM) for 1 hour and then with 20% NCS for 4 hours. Luciferase assays 
were as in figure 3. *** indicates a p-value ≤ 0.05.  
 
 Figure 8. AZD0530 inhibits Smad phosphorylation in vivo.  
A) NIH3T3 cells were serum-starved overnight and then treated with DMSO,  100 nM 
AZD0530 or 1µM Dorsomorphin for 1 hour followed by serum for  hour.  Serum-
induced phosphorylation was measured by immunoblotting using phospho-specific 
antibodies for phospho-Smad1/5/8, phospho ERK1/2, and phospho srcY416 .  Anti-actin 
antibodies were used as a loading control. B) SYF+/+ (wt fibroblasts)  and SYF-/- cells  
(null for src, yes and fyn) were starved in 0.2% serum overnight and induced with 20% 
serum for 1 hour.  Expression of Id1 and Id3 was measured by Q-PCR as in figure 1. 
 
Figure 9. AZD0530 inhibits BMP responsive ALKs in vitro. 
A) In vitro kinase assays were performed with the indicated purified ALK protein kinases 
at 10 different AZD0530 concentrations in triplicate.  The relative activities are shown. 
B) The IC50s of AZD0530 and a non-specific protein kinase inhibitor, staurosporine, are 
shown for each BMP receptor subunit. ND, not done. Alternative names for ALKs are 
shown. 
 
Figure 10.  AZD0530 inhibits the constitutive activation of the Id1 promoter by type 
1 BMP receptors.  
Constitutively active type 1 BMP receptors, ALK1 to 5 and ALK7 were transfected with 
the Id1 -1150 luciferase reporter gene along with pRLSV40P into NIH3T3 cells.  The 
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next day the media was changed to 0.2% serum containing AZD0530 (100 nM) or 
DMSO as a control and the cells were incubated overnight. Luciferase levels were 
measured as in figure 3. *** indicates a p-value ≤ 0.05.  
 
Figure 11.  AZD0530 inhibits constitutive Id1 expression in HCT116 colon cancer 
cells.  
HCT116 cells were serum starved in 0.2% serum overnight  with DMSO, AZD0530 (100 
nM)  or Dorsomorphin (1 µm).   These chemicals were added again the next day one hour 
before addition of 20% serum for one hour. A) Immunoblots for phospho-Smad 1/5/8 and 
actin control. B) Id1 mRNA levels were measured by Q-PCR as in figure 1. *** indicates 
a p-value ≤ 0.05.  
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SRF shRNA 2-2 cell line was generated by stable transfection of NIH3T3 with pLKO.1 
containing short hairpin RNA (shRNA) directed to SRF; shSRF-2, 5’ –
GAUGGAGUUCAUCGACAACAA -3’; NIH3T3 cells were used as the control cell 
line.  The lentiviruses were made in Phoenix-ECO cells (ATCC CRL3214). Cells were 
grown in 5% CO2 Dulbecco’s modified Eagle’s medium (DMEM) containing 10% New 
Born Calf serum (NCS) and 10 µg/ml puromycin (Invivogen). NIH3T3 cells were grown 
in 5% CO2 in DMEM supplemented with 10% NCS.   
 
 
Figure	  legends	  	  
 
Figure	  S1.	  	  Effect	  of	  SRF	  depletion	  on	  IEG	  expression. 
Control and SRF knockdown cells were starved in 0.2% NCS overnight and then serum 
induced with 20% NCS for 0, 30, 60 or 120 minutes.  Total RNA was isolated from the 
cells. The levels of the indicated genes were measured using quantitative real time-PCR 
(Q-PCR). 18s rRNA levels were used to normalize for overall RNA levels.  
 
Table	  S1.	  Effect	  of	  SRF	  depletion	  on	  serum	  induction	  of	  immediate	  early	  genes.	  	  	  
The indicated IEGs were assayed as in figures 1 and S1. The average percent decreases at 
the peak time of induction +/- the standard deviation is shown.  A decrease of greater 
than 50% was considered significant.  Genes whose induction was changed less than 50% 
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or increased in the SRF depleted cells were labeled as SRF independent.  The final 
column indicates the SRF dependence. 
 





































































































































































































































































































































	  	  	  	  	  	  	  	  	  	  












Cellular FBJ osteosarcoma 
oncogene (c-fos) 
c-fos AGCATGGGCTCTCCTGTCAAC GCCACGGAGGAGACCAGAGT 
Connective Tissue Growth 
Factor  
CTGF AACCGCAAGATTGGAGTGTGC GGTATTTGCAGCTGCTTTGGAAGG 
Cysteine Rich protein 61  cyr61 
 
TCCACCGCTCTGAAAGGGATCT TGGTGTTTACAGTTGGGCTGGAAG 
Cytochrome c oxidase 
subunit II  
cox2 GGCAGCAAATCCTTGCTGTTCCAA TCACCATAGAATCCAGTCCGGGTA 
Early growth response-1   egr1 
 
AACAACCCTATGAGCACCTGACCA ATAACTCGTCTCCACCATCGCCTT 





ereg GTTTCTCATCATAACCGCTGGA GTCCGTAACTTGATGGCACTG 
Heparin binding EGF like 
growth factor  
Hbegf AAGAGAGACCCATGCCTCAGGAAA ACTGGTAGAGTCAGCCCATGACA 
Inhibitor of DNA 
binding/differention1  
Id1 AACGGCGAGATCAGTGCCTT CCTCAGCGACACAAGATGCGAT 
Inhibitor of DNA 
binding/differentiation  
Id3 ACCTTCAGGTGGTCCTGGCA AGCTCCTCTTGTCCTTGGAGATCA 
Interleukin 6  
 
il6 TCCAGTTGCCTTCTTGGGACTGAT AAGTCTCCTCTCCGGACTTGTGAA 
Leukemia inhibitory factor  
 
LIF TCAGCGACAAAGTTACTCCACCGT AAGTGATGACAAAGCCCAACAGGC 
Mitogen inducible gene 6 
 
mig6 ACCATGGCCTACAATCTGAACTCC TTGACCTTGGAGATGGACCACACT 
Nocturnin  
 
noc TTCGCGTCATGCAGTGGAACAT TCAGGCACTTCCTCTCTTCCCATT 




inhibitor   
PAI AACAAGAGCCAATCACAAGGCACC TGAACCCTTTCCCAGAGACCAGAA 





tbsp ACTAGGCCTGTTCGTCTTCTCTCA CGCTGGTTATGATTGGCAGCTGAT 
Vinculin  
 
vcl GCCGGACCAACATCAGTGAT GCGCAGAGTAAAGCCAGCAT 
Zinc finger protein 36 
 
zfp36 ATTCGCGCCACCATGGATCT ACGGGATGGAGTCCGAGTTTATGT 









Inhibitor of DNA 


















	  	  	  	  	  	  	  	  	  	  	  	  	  




	  Our	  findings	  shed	  light	  on	  the	  serum	  regulation	  of	  the	  Ids.	  We	  found	  that	  Id1	  is	  regulated	  by	  BMP	  in	  serum	  through	  the	  presence	  of	  BREs	  in	  its	  promoter.	  	  We	  also	  showed	  that	  the	  Src	  inhibitor,	  AZD0530	  inhibits	  the	  serum/BMP2	  activation	  by	  directly	  inhibiting	  the	  BMP	  responsive	  type	  1	  receptors,	  ALK1-­‐3.	  	  There	  are	  still	  some	  unanswered	  questions.	  	  It	  would	  be	  interesting	  to	  find	  out	  whether	  other	  IEGs	  are	  regulated	  in	  a	  manner	  similar	  to	  the	  Ids.	  One	  possible	  way	  to	  answer	  this	  question	  is	  to	  treat	  BMP2	  induced	  NIH3T3	  cells	  with	  AZD0530	  and	  identify	  by	  microarray	  the	  IEGs	  whose	  expression	  changes.	  	  In	  addition,	  one	  could	  analyze	  at	  available	  data	  to	  identify	  BMP	  induced	  IEGs.	  Further,	  one	  should	  identify	  which	  of	  the	  BMP2	  induced	  genes	  are	  also	  induced	  by	  serum.	  	  	  This	  will	  ensure	  that	  the	  genes	  being	  studied	  are	  serum	  responsive.	  	  This	  can	  be	  accomplished	  by	  treatment	  of	  quiescent	  NIH3T3	  cells	  with	  serum	  and	  then	  checking	  gene	  activation	  of	  the	  BMP2	  induced	  IEGs	  by	  Q-­‐PCR.	  	  	  	  Interestingly	  cyr61	  was	  SRF	  independent	  even	  though	  it	  has	  known	  SREs	  [36].	  cyr61	  is	  up	  regulated	  by	  BMP4	  [207],	  therefore,	  	  it	  may	  also	  be	  regulated	  by	  a	  BMP	  pathway.	  AZD0530	  may	  not	  block	  its	  serum	  induction	  because	  it	  may	  also	  be	  induced	  in	  a	  BMP	  independent	  manner.	  	  This	  kind	  of	  regulation	  will	  not	  be	  unprecedented	  as	  the	  RhoA	  pathway	  of	  c-­‐fos	  regulation	  was	  only	  discovered	  after	  blocking	  the	  MAPK	  pathway	  [91].	  	  One	  way	  to	  test	  this	  may	  be	  to	  treat	  shSRF-­‐2	  cells	  with	  AZD0530	  and	  check	  serum/BMP	  induction	  of	  SRF	  independent	  IEGs	  such	  as	  cyr16.	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   AZD0530	  directly	  inhibits	  ALKs,	  however,	  Smads	  may	  be	  activated	  by	  pathways	  other	  than	  the	  one	  involving	  BMP	  receptors,	  for	  example	  the	  JNK	  and	  p38	  pathways	  [268].	  	  Treating	  other	  BMP2	  induced	  IEGs	  with	  AZD0530	  will	  identify	  the	  IEGs	  that	  are	  activated	  in	  a	  manner	  similar	  to	  Ids.	  However,	  in	  order	  to	  identify	  genes	  regulated	  differently,	  one	  may	  treat	  cells	  with	  inhibitors	  of	  these	  alternative	  pathways	  such	  as	  p38	  before	  induction	  of	  quiescent	  cells	  with	  BMP2.	  	  Another	  way	  to	  test	  this	  is	  to	  utilize	  BMP	  inhibitors	  such	  as	  noggin	  that	  prevent	  any	  BMP	  signaling.	  Microarray	  technology	  can	  be	  used	  to	  identify	  IEGs	  whose	  expression	  is	  inhibited	  by	  noggin.	  Another	  interesting	  finding	  was	  that	  c-­‐fos,	  the	  longest	  studied	  SRF	  dependent	  gene	  was	  found	  to	  be	  SRF	  independent.	  	  Understanding	  why	  this	  is	  so	  will	  shed	  light	  on	  how	  c-­‐fos	  is	  regulated.	  	  We	  discussed	  the	  possibility	  that	  there	  is	  a	  threshold	  of	  SRF	  binding	  or	  that	  there	  is	  another	  pathway	  that	  regulates	  c-­‐fos.	  In	  order	  to	  shed	  light	  on	  this	  the	  following	  experiments	  may	  be	  performed.	  	  Conditional	  knockout	  of	  SRF	  can	  be	  made	  in	  fibroblasts.	  	  Once	  the	  knockout	  has	  been	  confirmed	  the	  mRNA	  expression	  of	  c-­‐fos	  in	  response	  to	  serum	  treatment	  should	  be	  assayed.	  	  Reporter	  assays	  in	  these	  cells	  will	  indicate	  whether	  the	  promoter	  activity	  of	  c-­‐fos	  is	  affected	  by	  loss	  of	  SRF.	  	   If	  the	  knockout	  does	  not	  completely	  abolish	  c-­‐fos	  activation,	  this	  will	  indicate	  that	  there	  are	  additional	  regulatory	  elements	  in	  the	  c-­‐fos	  promoter	  that	  are	  regulated	  independent	  of	  SRF.	  	  We	  unsuccessfully	  attempted	  to	  find	  additional	  serum	  regulatory	  elements	  in	  the	  c-­‐fos	  promoter	  using	  reporter	  genes.	  This	  may	  be	  because	  we	  did	  not	  clone	  the	  region	  in	  which	  these	  elements	  are	  located.	  	  We	  can	  
	   	   	   	  
	  	  
111use	  available	  databases	  to	  identify	  regions	  of	  conservation	  in	  the	  c-­‐fos	  promoter.	  	  The	  putative	  regions	  can	  be	  cloned	  in	  front	  of	  the	  c-­‐fos	  minimal	  promoter,	  this	  would	  allow	  us	  to	  test	  whether	  these	  promoter	  regions	  are	  needed	  for	  serum	  induction	  of	  c-­‐fos.	  Finally	  we	  showed	  that	  that	  AZD0530	  blocks	  Id1	  expression	  in	  the	  HCT116	  colon	  cancer	  cell	  line	  in	  which	  the	  BMP	  pathway	  is	  deregulated.	  	  Id1	  overexpression	  /misregulation	  is	  present	  in	  many	  other	  cancers	  [269].	  	  Inhibiting	  BMP	  pathway	  expression	  of	  Id1	  presents	  a	  novel	  way	  to	  inhibit	  Id1	  in	  cancer.	  	  Bio-­‐informatics	  may	  be	  used	  to	  identify	  cancers	  in	  which	  Id1	  is	  upregulated	  and/or	  the	  BMP	  pathway	  is	  perturbed.	  Candidate	  cell	  lines	  can	  be	  treated	  with	  BMP	  pathway	  inhibitors	  such	  as	  AZD0530,	  dorsomorphin	  or	  noggin	  to	  check	  whether	  this	  affects	  BMP	  signaling.	  	  The	  effect	  on	  Id1	  expression	  can	  be	  assayed	  by	  Q-­‐PCR	  and	  the	  effect	  on	  phospho-­‐Smad1/5/8	  by	  immunoblotting.	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